🇺🇸 FDA
Pipeline program

rAAV9.CMV.hNAGLU

ABT-002

Phase 2 mab terminated

Quick answer

rAAV9.CMV.hNAGLU for Mucopolysaccharidosis Type 3 B is a Phase 2 program (mab) at ABEONA THERAPEUTICS INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ABEONA THERAPEUTICS INC.
Indication
Mucopolysaccharidosis Type 3 B
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials